Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105
Peer-review started: May 16, 2023
First decision: July 18, 2023
Revised: July 18, 2023
Accepted: August 17, 2023
Article in press: August 17, 2023
Published online: September 16, 2023
Processing time: 114 Days and 21.2 Hours
Coronavirus disease 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021-year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipiravir.
To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing the need for invasive mechanical ventilation (IMV).
265 COVID-19 polymerase chain reaction confirmed patients with indication for antiviral therapy were included in this study and were divided into 3 groups (1: 2: 2): Group A: REGN3048-3051 antibodies cocktail (casirivimab and imdevimab), group B: Remdesivir, group C: Favipiravir. The study design is a single-blind non-randomized controlled trial Mansoura University Hospital owns the study’s drugs. The duration of the study was about 6 mo after ethical approval.
Casirivimab and imdevimab achieve less need for O2 therapy and IMV, with less duration of this need than remdesivir and favipiravir.
Group A (casirivimab and imdevimab) achieve better clinical outcomes than groups B (remdesivir) and C (favipiravir) intervention groups.
Core Tip: This research can benefit the coronavirus disease 2019 (COVID-19) patients by determining the most appropriate antiviral drug according to the case. This study may change the protocol of treatment of COVID-19 patients. Casirivimab and imdevimab achieve better clinical outcomes than remdesivir and favipiravir.